Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04051463 · ClinicalTrials.gov registry record · Phase 2
Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
A Phase 2 study, sponsored by Price Vision Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT04051463 is a Phase 2 study that has completed, run by Price Vision Group. The registered enrollment target is 29 participants.
The verdict
NCT04051463, a Phase 2 study, has completed, sponsored by Price Vision Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The study objective is to determine whether use of Rhopressa improves the ability of corneal endothelial cells to maintain appropriate corneal hydration in patients with Fuchs endothelial corneal dystrophy (FECD), which could help delay or prevent the need for a corneal transplant.
Interventions
- DRUG Placebo
- DRUG Netarsudil Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2020-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04051463
The ClinicalTrials.gov registry entry for NCT04051463 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Price Vision Group, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04051463 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04051463 about?
NCT04051463 is a clinical study titled "Rhopressa for Corneal Edema Associated With Fuchs Dystrophy". The study objective is to determine whether use of Rhopressa improves the ability of corneal endothelial cells to maintain appropriate corneal hydration in patients with Fuchs endothelial corneal dystrophy (FECD), which could help delay or prevent the need for a corneal transplant.
What is the current status of trial NCT04051463?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2019-08-05. Estimated completion is 2020-07-01.
What interventions are being tested in trial NCT04051463?
The interventions under investigation include: Placebo (DRUG), Netarsudil Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT04051463?
This trial is sponsored by Price Vision Group, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.